Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Daniel Ostrowski

Nurse Practitioner, Family Staten Island, NY Nurse Practitioner

NPI 1740648922 CMS profile 11066240

27 New Dorp Ln Ste 1, Staten Island, NY 10306

Open in the dashboard

General payments

$25,060

887 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Ostrowski of Staten Island, NY is reported in the CMS Open Payments database as having received $25,060 across 887 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,882 205
2024 General $6,807 225
2023 General $4,120 164
2022 General $3,428 129
2021 General $5,823 164

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Ostrowski
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Daniel Ostrowski were reported at $4,882. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Daniel Ostrowski Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $5,823 $124 $35–$379 $132
2022 $3,428 $141 $44–$430 $149
2023 $4,120 $154 $49–$476 $160
2024 $6,807 $165 $51–$504 $164
2025 $4,882 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,293 163 payments
  2. EMD Serono, Inc. $2,418 36 payments
  3. Teva Pharmaceuticals USA, Inc. $2,137 86 payments
  4. Biogen, Inc. $1,784 79 payments
  5. Neurocrine Biosciences, Inc. $993 31 payments
  6. Otsuka America Pharmaceutical, Inc. $974 14 payments
  7. Biohaven Pharmaceuticals, Inc. $970 20 payments
  8. ANI Pharmaceuticals, Inc. $810 42 payments
  9. Axsome Therapeutics, Inc. $550 15 payments
  10. Celgene Corporation $546 27 payments
  11. Other $9,586 374 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $24,970 886 payments
  2. Education $90 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $3,136 117 payments
  2. QULIPTA $1,551 53 payments
  3. Austedo XR $1,453 52 payments
  4. NURTEC ODT $1,207 32 payments
  5. Mavenclad $940 8 payments
  6. REXULTI $835 12 payments
  7. ZEPOSIA $740 32 payments
  8. TYSABRI $726 38 payments
  9. PURIFIED CORTROPHIN GEL $607 30 payments
  10. OCREVUS $596 18 payments
  11. Other $12,608 500 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

887 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record